# Phase II Study of Histone-deacetylase Inhibitor ITF2357 in Refractory/Relapsed Lymphocytic Leukemia

> **NCT00792831** · PHASE2 · TERMINATED · sponsor: **Italfarmaco** · enrollment: 3 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** ITF2357

## Key facts

- **NCT ID:** NCT00792831
- **Lead sponsor:** Italfarmaco
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-02
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Protocol needs complete restructuring in order to make it feasible and to complete the enrollment of 23 patients.
- **Last updated:** 2022-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00792831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00792831, "Phase II Study of Histone-deacetylase Inhibitor ITF2357 in Refractory/Relapsed Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00792831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*